Loading…
Illumina, Inc. is projected to rise to $177.73 by 2027, a +18% move from its current price of $150.17. ILMN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $147.34 | $150.17 | $153.06 | 0.00% |
| May 30 | $146.19 | $150.18 | $154.28 | 0.00% |
| May 31 | $145.31 | $150.18 | $155.22 | +0.01% |
| Jun 1 | $144.57 | $150.18 | $156.02 | +0.01% |
| Jun 2 | $143.92 | $150.19 | $156.72 | +0.01% |
| Jun 3 | $143.34 | $150.19 | $157.37 | +0.01% |
| Jun 4 | $142.81 | $150.20 | $157.96 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $142.81 | $150.20 | $157.96 | +0.02% |
| Week 2 | $139.89 | $150.22 | $161.32 | +0.03% |
| Week 3 | $137.69 | $150.25 | $163.95 | +0.05% |
| Week 4 | $135.86 | $150.27 | $166.21 | +0.07% |
| Week 5 | $134.28 | $150.30 | $168.23 | +0.08% |
| Week 6 | $132.86 | $150.32 | $170.08 | +0.10% |
| Week 7 | $131.58 | $150.35 | $171.80 | +0.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Illumina, Inc. is a healthcare company that provides sequencing- and array-based solutions for genetic and genomic analysis across the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. It offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors.
The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease.
Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Illumina, Inc. (ILMN) is a healthcare company focused on sequencing- and array-based genetic and genomic analysis solutions. Its current price is $144.41 and its market capitalization is $21.85B, with a rank of 558.
The stock sits within a forecast that projects gradual to strong upside over the coming years, driven by higher average prices in the years beyond 2026. The forecast shows a path from 2026 to 2050 with rising averages and substantial longer-term upside.
A major floor 26.5% below — a decisive break under it would weaken the trend.
The nearest floor, 19.8% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 13.2% above — clearing it would confirm fresh momentum.
Key ILMN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ILMN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $145.31 | Buy | $146.10 | Buy |
| MA 10 | $144.05 | Buy | $144.22 | Buy |
| MA 20 | $140.66 | Buy | $141.01 | Buy |
| MA 50 | $132.23 | Buy | $135.30 | Buy |
| MA 100 | $132.64 | Buy | $130.88 | Buy |
| MA 200 | $121.62 | Buy | $124.35 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 69.10 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 144.28 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.27 | Buy |
| ROC (12) | 5.84 | Buy |
| Bollinger %B (20,2) | 0.87 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.44 | Buy |
| Awesome (5,34) | 9.47 | Buy |
| Ultimate (7,14,28) | 76.91 | Sell |
| Momentum (10) | 4.47 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 147.10 | Buy |
| ADX (14) | 21.21 | Buy |
| ATR (14) | 2.22 | Info |
The 30-day technical picture shows a bullish tilt in sentiment, with RSI14 at 60. The stock trades above the SMA50 of $131.09 and above the SMA200 of $121.09, signaling constructive momentum near key moving averages. Near-term support is at $120.37 and resistance at $145.70, with a 30-day price range of $127.45 to $163.62.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $114.44 | $150.17 | $194.62 | 0% | Neutral | |
| $145.09 | $177.73 | $227.96 | +18% | Neutral | |
| $151.14 | $188.56 | $248.23 | +26% | Bullish | |
| $178.96 | $226.69 | $304.71 | +51% | Bullish | |
| $214.08 | $274.84 | $376.02 | +83% | Bullish | |
| $229.67 | $298.45 | $414.75 | +99% | Bullish | |
| $262.95 | $345.58 | $487.05 | +130% | Bullish | |
| $279.11 | $370.70 | $529.20 | +147% | Bullish | |
| $279.91 | $375.49 | $542.45 | +150% | Bullish | |
| $307.34 | $416.21 | $607.97 | +177% | Bullish | |
| $468.51 | $662.01 | $1,013.49 | +341% | Bullish | |
| $811.25 | $1,230.39 | $2,019.69 | +719% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $114.44 | $150.17 | $176.21 | +0.00% |
| June 2026 | $130.02 | $151.70 | $180.45 | +1.02% |
| July 2026 | $128.24 | $150.50 | $180.73 | -0.79% |
| August 2026 | $130.46 | $153.80 | $186.05 | +2.19% |
| September 2026 | $133.34 | $157.79 | $192.02 | +2.59% |
| October 2026 | $131.70 | $156.38 | $191.34 | -0.89% |
| November 2026 | $130.04 | $154.88 | $190.42 | -0.96% |
| December 2026 | $131.94 | $157.59 | $194.62 | +1.75% |
Click any year to see its month-by-month ILMN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ILMN price prediction for 2026 points to an average of $150.17 (low $114.44, high $194.62) — a potential gain of 0% on today's $150.17. A consolidation phase looks the most probable path here.
In 2027, ILMN is projected to trade between $145.09 and $227.96, averaging $177.73 — a potential gain of +18% from today's $150.17. That is up +18% on the projected 2026 average. Price action looks broadly range-bound.
Illumina, Inc.'s 2028 outlook centres on $188.56, within a $151.14 to $248.23 range. That is up +6% on the projected 2027 average. That marks a +26% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ILMN could reach as high as $304.71, with a base case around $226.69 and support toward $178.96 — roughly +51% from $150.17. Momentum favours further upside here.
Expect ILMN to range from $214.08 to $376.02 through 2030. The $274.84 average target implies a +83% move from current prices. That is up +21% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ILMN price prediction for 2031 points to an average of $298.45 (low $229.67, high $414.75) — a potential gain of +99% on today's $150.17. Momentum favours further upside here.
In 2032, ILMN is projected to trade between $262.95 and $487.05, averaging $345.58 — a potential gain of +130% from today's $150.17. That is up +16% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Illumina, Inc.'s 2033 outlook centres on $370.70, within a $279.11 to $529.20 range. That is up +7% on the projected 2032 average. That marks a +147% change versus current levels. Momentum favours further upside here.
By 2034, ILMN could reach as high as $542.45, with a base case around $375.49 and support toward $279.91 — roughly +150% from $150.17. Buyers look set to stay in control over this stretch.
Expect ILMN to range from $307.34 to $607.97 through 2035. The $416.21 average target implies a +177% move from current prices. That is up +11% on the projected 2034 average. Momentum favours further upside here.
The ILMN price prediction for 2040 points to an average of $662.01 (low $468.51, high $1,013.49) — a potential gain of +341% on today's $150.17. Buyers look set to stay in control over this stretch.
In 2050, ILMN is projected to trade between $811.25 and $2,019.69, averaging $1,230.39 — a potential gain of +719% from today's $150.17. That is up +86% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ILMN today (≈ 6.65912 ILMN) could be worth
$8,193.32
+$7,193.32 (+719%) by 2050 · US Dollar
Based on the average projected ILMN price of $1,230.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ILMNwould be worth at today's price.
$1,000 invested in ILMN on May 27, 2025 (≈ 12.122682 ILMN) would be worth
$1,820.46
+$820.46 (+82.0%) today · 1.82× · US Dollar
Based on a ILMN entry price of $82.49 vs. today's $150.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $141.92 | $1,058.13 | +5.8% |
| 1 month ago | $128.52 | $1,168.46 | +16.8% |
| 3 months ago | $127.4 | $1,178.73 | +17.9% |
| 6 months ago | $131.45 | $1,142.41 | +14.2% |
| 1 year ago | $82.49 | $1,820.46 | +82.0% |
| All time (5.0y) ago | $396.35 | $378.88 | -62.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ILMN forecast.
Our base-case forecast reaches $300.00 around 2032.
Implied market cap at $300.00: $45.39B
The multi-year forecast outlines a clear ascent from 2026 through 2050. The 2026 forecast shows an average of $144.41 with a min of $114.44 and a max of $186.66 (ROI 0) and a neutral sentiment. From 2027 onward, the averages rise to $167.90 (min $137.07, max $215.33; ROI 16.3), 2028 $177.91 (min $142.64, max $234.15; ROI 23.2), 2029 $211.75 (min $167.22, max $284.48; ROI 46.6), 2030 $253.12 (min $197.26, max $346.11; ROI 75.3), 2031 $275.13 (min $211.83, max $382.08; ROI 90.5), 2032 $317.97 (min $242.10, max $447.80; ROI 120.2), 2033 $337.50 (min $254.29, max $481.42; ROI 133.7), 2034 $340.90 (min $254.32, max $492.04; ROI 136.1), 2035 $377.57 (min $279.03, max $551.00; ROI 161.4).
The path continues to 2040 with an average of $591.88 (min $419.35, max $905.05; ROI 309.9) and 2050 with an average of $1,081.57 (min $714.29, max $1,772.74; ROI 649). Sentiment shifts to bullish from 2028 onward, reflecting a longer-term acceleration in price forecasts, with the max forecast reaching $1,772.74 in 2050. These figures are estimates of future prices and are not guarantees of performance; they reflect the projected long-term trajectory and associated risk.
Tap a question to reveal the answer.
2030 avg $253.12; min $197.26; max $346.11; ROI 75.3; sentiment BULLISH.
The forecast shows a path of rising averages with bullish sentiment from 2028 onward and a 2030 avg of $253.12, 2040 avg of $591.88, and 2050 avg of $1,081.57. ROI figures rise to 75.3 by 2030, 309.9 by 2040, and 649 by 2050, indicating potential upside but these are estimates, not guarantees.
Yes. The max forecast in 2050 is $1,772.74 and the average in 2050 is $1,081.57, corresponding to a high upside scenario within the forecast window.
Current price is $144.41 and market cap is $21.85B.
RSI14 is 60, SMA50 is $131.09, SMA200 is $121.09. Support is $120.37 and resistance is $145.70, with a 30-day range of $127.45 to $163.62 and an annualized volatility of 40%.
Illumina, Inc. Community Discussion
0Share your Illumina, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.